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Abstract.
Introduction: Splanchnic venous  thrombosis (SVT)  has  varied  etiology with  Philadelphia- negative   myeloproliferative 
neoplasms   (MPNs)   being   the   most   frequent   underlying prothrombotic factor. Hematological indices often remain 
within normal range because of  portal hypertension and its  sequelae, causing diagnostic challenges. The high frequency of  
JAK2 mutation among patients with SVT reinforces the diagnostic utility of  JAK2V617F testing.
Case report: We report a case of  a 62-year-old black man with progressive abdominal swelling and features of  decompen-
sated chronic liver disease found to have SVT- portal vein thrombosis and how JAK2 V617F was useful in unmasking an 
underlying myeloproliferative neoplasm.
Conclusion: A high index of  suspicion for an underlying prothrombotic factor is critical for patients presenting with throm-
bosis in unusual sites. This is useful in prognostic stratification and patient outcomes. JAK2 mutation screening is now part 
of  the standard diagnostic workup in SVT.
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Introduction
Splanchnic venous thrombosis (SVT) is a rare but life-
threatening form of  venous thrombosis and includes 
hepatic vein thrombosis (Budd-Chiari syndrome, BCS), 
portal vein thrombosis (PVT) and mesenteric vein 
thrombosis (MVT)1.  Involvement of  two or more ab-
dominal vein segments usually occurs2. A thrombotic 
event in unusual sites such as intra-abdominal veins is 
cause for further evaluation of  an underlying hyper-
coagulable state, both inherited and acquired throm-
bophilias. A more frequent association between Phila-
delphia-negative myeloproliferative neoplasms (MPNs) 
and SVT, in particular PVT and BCS, has been reported 
3,4. The MPNs are a related group of  diseases with a 
common origin of  an acquired stem cell defect leading 
to over proliferation of  the myeloid series. Diagnosis 
of  occult forms of  MPNs may be difficult in the set-
ting of  SVT because of  the near normal hematologi-
cal indices resulting from portal hypertension. Nearly 
a decade ago, it was demonstrated that MPNs are con-
nected by an acquired somatic mutation in the JAK2 
gene, the JAK2 V617F mutation5. All patients with idi-
opathic intra-abdominal venous thrombosis should be 
screened for JAK2 V617F mutation in order to detect 
latent or occult MPNs6.
Case report
A 62-year-old black man of  Tanzanian nationality 
growing up in the mountainous areas of  Kilimanjaro 
presented to Mulago hospital with a 6 weeks history of  
progressive abdominal swelling associated with nausea 
and occasional non-projectile vomiting without hemate-
mesis. Two weeks into admission, he developed pain in 
the right upper quadrant of  the abdomen. He affirmed 
complaints of  poor appetite and early satiety but nor-
mal bowel movements. He reported significant loss of  
weight, with associated low-grade fevers but no drench-
ing sweats. His medical history was notable for systemic 
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hypertension two years prior to admission that was con-
trolled on lisinopril and propranolol. He was also on 
low dose aspirin for the prevention of  cerebrovascular 
events. He denied a history of  liver disease, blood dis-
orders or cancer. He was married with four children and 
was an agricultural researcher. He had never smoked 
cigarettes but drank 1-2 bottles of  beer on weekends.
Initial physical evaluation revealed a jaundiced man, 
with mild pedal edema, hepatomegaly of  4 cm below 
the costal margin, and moderate ascites. A clinical di-
agnosis of  decompensated liver disease with portal hy-
pertension was made and a number of  tests were done 
to exclude etiology and  complications of   liver  dis-
ease.  Laboratory tests  revealed  a  marked transaminitis 
with; Alanine Aminotransferase at 1247U/L [30x ULN 
(upper limit of  normal)], Aspartate Aminotransferase 
was 773U/L (20xULN), Total bilirubin 134µmol/L 
(7.8xULN), direct fraction was 66.2 µmol/L (19xULN) 
gamma glutamyl transferase was 365U/L (5.5x ULN). 
Renal function tests were normal as well as fasting li-
pids and glucose. Ascitic fluid analysis showed protein 
of  2.1g/dl, white cell count of  100cells/mm3 with 80% 
lymphocytosis. Unfortunately, ascitic fluid albumin was 
not done making it impossible to determine serum-as-
cites albumin gradient (SAAG).
Complete blood count (CBC) on admission showed 
a total white cell count (WBC) of  9.82 x103/µL, hae-
moglobin of  18.5 g/dL, haematocrit of  54% and a 
rather high platelet count of  660 x103/µL. Serological 
markers for hepatitis B virus (HBV), hepatitis C virus 
(HCV) and the human immunodeficiency virus (HIV) 
were all negative. Tumor markers including Ca-19-9, 
CEA, total prostatic specific antigen (PSA) and alpha 
feto protein(AFP) were normal. Autoimmune screen 
was negative for Anti-nuclear factor and smooth mus-
cle antibodies. S-ceruloplasmin at 33mg/dL, and pro-
thrombin time were normal. Abdominal ultrasonogra-
phy showed a splenomegaly and a hypodense lesion in 
the left lower lobe of  the liver that revealed coagulative 
necrosis on histology consistent with hepatic infarction 
without evidence of  malignancy.
Doppler ultrasound studies of  the abdomen showed 
features of  portal vein thrombosis with absent colour 
flow mapping in the portal veins but hepatic veins were 
not demonstrable. A subsequent doppler scan of  both 
legs showed stagnation of  flow in the deep calf  veins 
and marked varicose veins bilaterally. The patient was 
initiated on anticoagulation with enoxaparin. A JAK2 
V617F mutation assay was positive but without allele 
percentage. The patient while in hospital  developed 
renal  impairment,  hepatic  encephalopathy,  and  prob-
able  variceal hemorrhage leading to death.
Discussion
Based on the new-onset SVT combined with the find-
ing of  the JAK2 V617F mutation, our patient’s condi-
tion was diagnosed as an underlying chronic MPN. The 
clinical presentation of  SVT  varies  according to  the 
extent, rapidity of   obstruction and  venous segment 
involved. Specifically looking at PVT, presentation may 
be asymptomatic, acute or chronic. Acute thrombosis 
is characterized by a sudden onset of  abdominal pain 
without evidence of  chronic portal hypertension (gas-
trointestinal bleeding, ascites, collateral portosystemic 
circulation or hypersplenism). Sonography may show 
hyperechoic material in the vessel lumen with disten-
sion of  the portal veins and its tributaries. 
Doppler imaging shows the absence of  flow in part or 
all the lumen7,8. As demonstrated in the patient, chronic 
PVT is a late sequela of  thrombosis usually defined by 
the presence of  a portal cavernoma with features of  
portal hypertension. At imaging, a diagnosis of  carver-
noma is readily made by abdominal imaging with ultra-
sound, computed tomography or magnetic resonance 
scan which shows serpiginous structures while the main 
portal vein and or its branches are not visible7, 9. Many 
large-scale studies have been performed to  study the 
underlying etiological factors in  SVT. Both inherited 
and acquired thrombophilias are frequently observed 
in these patients. Philadelphia-negative MPNs are the 
most frequent underlying prothrombotic factor in BCS 
and PVT, with a reported prevalence of  30%-50% and 
15%-30% respectively7,10. 
Markers of  Philadelphia-negative MPNs such as endog-
enous erythrocyte colony formation by bone marrow 
and peripheral blood cells, JAK2 mutation and the in-
creased mRNA expression of  PRV-1 in polymorphonu-
clear neutrophils have gained strong popularity among 
clinicians because it represents significant improvement 
in prognostic stratification and therapeutic manage-
ment of  patients with SVT. Other etiological factors 
are paroxysmal nocturnal hemoglobinuria (PNH), au-
toimmune disorders, intra-abdominal inflammatory 
conditions, postoperative state, sickle cell anemia, an-
ti-phospholipid syndrome, inherited hypercoagulable 
states (thrombophilias), including factor V Leiden, pro-
thrombin G20210A mutation, protein C, protein S and 
anti-thrombin deficiencies. 
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Images of liver biopsy showing sharply demarcated areas of coagulative necrosis consistent with a defined infarct. 
Diagnosis transmitted electronically from Cincinnati, Ohio, USA 
Diagnosis of  MPN in the setting of  SVT can how-
ever, be challenging owing to the near normal periph-
Table  1  below  shows  the  prevalence  of  thrombotic  risk  factors  in  a  series  of  
routinely investigated  consecutive  adult  patients  with  non-tumorous  and  non-cirrhotic,  
acute  and  or 
chronic PVT and BCS. 
 
Risk Factors PVT patients BCS patients 
Myeloproliferative disorders 30%-40% 40%-50% 
Atypical 14% 25%-35% 
Classical 17% 10%-25% 
Antiphospholipid syndrome 6%-19% 4%-25% 
Paroxysmal nocturnal hemoglobinuria 0%-2% 0%-4% 
Behcet’s disease 0% -31% 0%-33% 
Factor V Leiden mutation 6%-32% 6%-32% 
Factor II mutation 14%-40% 5%-7% 
Protein C deficiency* 0%-26% 10%-30% 
Protein S deficiency* 2%-30% 7%-20% 
Antithrombin deficiency* 0%-26% 0%-23% 
Plasminogen deficiency* 0%-6% 0%-4% 
Recent pregnancy 6%-40% 6%-12% 
Recent oral contraceptive use 12% 6%-60% 
Hyperhomocysteinemia 12%-22% 37% 
TT677 MTHFR genotype 11%-50% 12%-22% 
 
*Regarded as preceding the development of PVT 
or BCS. 
Adapted from American Association for the Study of Liver Diseases practice Guidelines, 2008 
eral blood cell counts because of  portal hypertension 
and its sequelae (splenomegaly, hemodilution and iron 
deficiency)10.
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The discovery of  the JAK2 V617F gain-of-function 
mutation in 2005, found in 95% of  patients with poly-
cythemia vera (PV) and in 50%-60% of  patients with 
essential thrombocythemia and myelofibrosis, repre-
sents a crucial advance in the diagnostic approach to 
MPNs in the setting of  SVT10,11. The goals of  therapy 
in patients with MPNs are to avoid thrombotic and 
bleeding complications and also to monitor for pro-
gression to acute leukemia and myelofibrosis. In a ret-
rospective multivariate analysis of  a large cohort includ-
ing patients with chronic or acute PVT, it was found 
that anticoagulation therapy significantly decreased the 
risk of  recurrent thrombosis without increasing the risk 
of  gastrointestinal bleeding12,13.  Recent case series on 
myeloproliferative neoplasms stratify care according to 
thrombotic risk into low risk (defined by  absence of  
prior  thrombosis and  age <60  years),  and  high  risk 
(defined by  history of  thrombosis,  or  age >60  years, 
poor  compliance  to  phlebotomy,  or  progressive 
myeloproliferation, i.e. splenomegaly, leucocytosis and 
thrombocytosis). Although our patient had no history 
of  thrombosis, he met the high risk criteria. 
In polycythemia vera, low risk patients can be managed 
by phlebotomy to maintain hematocrit <0.45 and low-
dose aspirin, while high  risk  patients  require cytore-
ductive therapies with  hydroxyurea and  interferon-α. 
Busulfan can be used in elderly patients >75 years. For 
patients with essential thrombocythemia, anagrelide 
can be considered as second line therapy. Long term 
oral anticoagulation is useful in secondary prevention 
of  thrombosis without significant increase in risk of  
major bleeding14,15. There is insufficient evidence in fa-
vour of  interventional therapy and no consensus on the 
management of   chronic portal  vein  obstruction. In 
case  of   worsening on  medical therapy, patients should 
be considered for invasive procedures like angioplasty/
stenting, transjugular intrahepatic portosystemic shunt-
ing and liver transplantation16.
Hoekstra et al in their retrospective cohort study on 
long-term follow-up of  patients with PVT and MPNs 
reported that mortality was primarily related to the un-
derlying MPN and not to complications of  portal hy-
pertension17. Unfortunately our patient, though he had 
commenced anticoagulation and paracentesis, did not 
undergo phlebotomy or cytoreductive therapy. It was 
therefore impossible to assess the impact of  these in-
terventions on the patient’s outcome.
Study limitations included the lack of  thrombophilia 
screen, although results would have been difficult  to 
interpret  in  the  setting  of   liver  failure  and  anti-
coagulation.  Abdominal  CT- angiography would have 
been useful in delineating vascular occlusion in BCS. 
Furthermore, sub- classification of  the specific MPN 
with the help of  additional tests including red cell mass 
determination was not done. Endoscopy was also not 
done because of  the critical state of  the patient.
Conclusion
In conclusion, a high index of  suspicion for an underly-
ing hypercoagulable state is required for patients pre-
senting with thrombosis in unusual sites. This will lead 
to early definitive diagnosis, inform treatment and im-
prove patient outcomes.
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